GSEP
NBIX icon

Golden State Equity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Golden State Equity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.2K Buy
+305
New +$40.5K ﹤0.01% 930
2024
Q4 		– Sell
-260
Closed -$30K – 705
2024
Q3 		$30K Buy
+260
New +$35.6K 0.02% 462

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Golden State Equity Partners's NBIX Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 305 shares worth $40.2K. The stake represents ﹤0.01% of the portfolio and ranks #930 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in NBIX as recently as Q3 2024.

Golden State Equity Partners first reported a position in NBIX in Q3 2024 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Golden State Equity Partners held 305 shares of Neurocrine Biosciences worth $40.2K as of Q1 2026.
  • Neurocrine Biosciences was a new Golden State Equity Partners position in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #930 holding.
  • Golden State Equity Partners first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.